Press Releases

Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules through partnership with China’s leading biopharmaceutical company, Hansoh Pharma.

Hansoh Pharmaceutical Group Company Limited, a leading biopharmaceutical company in China, and Atomwise, Inc., the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.

Atomwise and Atropos Therapeutics form a joint venture to discover and develop anticancer agents using senescence assay and AI technologies.

Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients SEATTLE, Wash., and SAN FRANCISCO, Calif. – SEngine Precision Medicine and Atomwise, Inc. today announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development. […]

Ann Arbor, Michigan – From making pain management safer and more effective to identifying inhibitors for a fibrosis target protein and more, researchers from Michigan Medicine, as well as the University of Michigan College of Pharmacy and U-M Life Sciences Institute, are looking to advance their projects through Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards […]

Atomwise, Enamine, and top university researchers collaborate to discover novel small molecules for the treatment of pediatric cancers using the power of AI and novel chemistry. SAN FRANCISCO, Calif., and KIEV, Ukraine, June 24, 2019 – Atomwise, Inc. today announced the launch of a 10 billion compound AI-powered virtual drug screening initiative, the 10-to-the-10 program, […]